Biomed outfit readies for US

LOCAL ASX-listed biomedical company Xcell Diagnostics hopes to operate a US subsidiary by the end of the year to open up the American market for its revolutionary skin cancer detection device developed by its recent acquisition, German medical technology company Visiomed AG.